Erythropoietin in amyotrophic lateral sclerosis: A multicentre, randomised, double blind, placebo controlled, phase III study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 8, 2015, Pages 879-886

  Lauria, Giuseppe ^a   Bella, Eleonora Dalla ^a   Antonini, Giovanni ^b   Borghero, Giuseppe ^c   Capasso, Margherita ^d   Caponnetto, Claudia ^e   Chiò, Adriano ^f   Corbo, Massimo ^g,h   Eleopra, Roberto ⁱ   Fazio, Raffaella ^j   Filosto, Massimiliano ^k   Giannini, Fabio ^l   Granieri, Enrico ^m   Bella, Vincenzo La ⁿ   Logroscino, Giancarlo ^o   Mandrioli, Jessica ^p   Mazzini, Letizia ^q   Monsurrò, Maria Rosaria ^r   Mora, Gabriele ^s   Pietrini, Vladimiro ^t   Quatrale, Rocco ^u   Rizzi, Romana ^v   Salvi, Fabrizio ^w   Siciliano, Gabriele ^x   Sorarù, Gianni ^y   Volanti, Paolo ^s   Tramacere, Irene ^a   Filippini, Graziella ^a   more..

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d Ss Annunziata Hospital   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^g NEMO Clinical Centre   (Italy)

^h DEPARTMENT OF NEUROREHABILITATION SCIENCES   (Italy)

ⁱ SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^j SAN RAFFAELE HOSPITAL   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l UNIVERSITY OF SIENA   (Italy)

^m UNIVERSITY OF FERRARA   (Italy)

ⁿ UNIVERSITY OF PALERMO   (Italy)

^o UNIVERSITY OF BARI   (Italy)

^p S Agostino Estense Hospital   (Italy)

^q University Hospital Maggiore della Carita   (Italy)

^r SECOND UNIVERSITY OF NAPLES   (Italy)

^s IRCCS   (Italy)

^t UNIVERSITY OF PARMA   (Italy)

^u Dell'Angelo Hospital   (Italy)

^v S MARIA NUOVA HOSPITAL   (Italy)

^w RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^x UNIVERSITY OF PISA   (Italy)

^y UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN; RILUZOLE; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ADD ON THERAPY; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; ITALY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONINVASIVE VENTILATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLOW VITAL CAPACITY; TRACHEOSTOMY; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DOUBLE-BLIND METHOD; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84940947280     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308996     Document Type: Article

References (37)

1. Solling C. Organ-protective and immunomodulatory effects of erythropoietin-an update on recent clinical trials. Basic Clin Pharmacol Toxicol 2012;110:113-21.
2. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42.
3. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-12.
4. Sanchez PE, Fares RP, Risso JJ, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci USA 2009;106:9848-53.
5. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044-9.
6. Mennini T, De Paola M, Bigini P, et al. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 2006;12:153-60.
7. Chung YH, Joo KM, Kim YS, et al. Enhanced expression of erythropoietin in the central nervous system of SOD1(G93A) transgenic mice. Brain Res 2004;1016:272-80.
8. Grunfeld JF, Barhum Y, Blondheim N, et al. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp Neurol 2007;204:260-3.
9. Grignaschi G, Zennaro E, Tortarolo M, et al. Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. Amyotroph Lateral Scler 2007;8:31-5.
10. Cho GW, Kim GY, Baek S, et al. Recombinant human erythropoietin reduces aggregation of mutant Cu/Zn-binding superoxide dismutase (SOD1) in NSC-34 cells. Neurosci Lett 2011;504:107-11.
11. Janik P, Kwiecinski H, Sokolowska B, et al. Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neural Transm 2010;117:343-7.
12. Just N, Moreau C, Lassalle P, et al. High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. Neuromuscul Disord 2007;17:169-73.
13. Lauria G, Campanella A, Filippini G, et al. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler 2009;10:410-15.
14. Kaufmann P, Levy G, Thompson JL, et al. The ALSFRSr. predicts survival time in an ALS clinic population. Neurology 2005;64:38-43.
15. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31.
16. Banks WA, Jumbe NL, Farrell CL, et al. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol 2004;505:93-101.
17. Xenocostas A, Cheung WK, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005;61:189-95.
18. Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007;130(Pt 10):2577-88.
19. Fond G, Macgregor A, Attal J, et al. Treating patients with schizophrenia deficit with erythropoietin? Psychiatry Clin Neurosci 2012;66:375-82.
20. Haljan G, Maitland A, Buchan A, et al. The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial. Stroke 2009;40:2769-75.
21. Cheung WK, Goon BL, Guilfoyle MC, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998;64:412-23.
22. Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004;101:823-8.
23. Chio A, Canosa A, Gallo S, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology 2011;77:1432-7.
24. Logroscino G, Traynor BJ, Hardiman O, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008;79:6-11.
25. Millul A, Beghi E, Logroscino G, et al. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology 2005;25:114-19.
26. del Aguila MA, Longstreth WT Jr. McGuire V, et al. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-19.
27. Pupillo E, Messina P, Logroscino G, et al. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 2014;75:287-97.
28. Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013;12:1059-67.
29. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-53.
30. Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;69:776-84.
31. Meininger V, Drory VE, Leigh PN, et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009;10:378-83.
32. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:481-8.
33. Beghi E, Pupillo E, Bonito V, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:397-405.
34. Chio A, Mora G, La Bella V, et al. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 2011;43:189-95.
35. Dupuis L, Dengler R, Heneka MT, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE 2012;7:e37885.
36. de Carvalho M, Pinto S, Costa J, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:456-60.
37. Meininger V, Bensimon G, Bradley WR, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:107-17.